19 May 2014 – Biosensors International has launched Chroma™, its innovative cobalt chromium bare-metal stent (BMS).
The novel platform combines straight and s-shaped link connectors, providing enhanced longitudinal strength while maintaining flexibility. This unique design, combined with the cobalt chromium alloy, results in a robust BMS with thin struts, offering exceptional deliverability while retaining excellent radial strength and extremely low recoil. Chroma’s large cell opening also provides ease of access to side branches when necessary. Chroma is deployed using an advanced delivery system, featuring the smallest tip entry profile in the Biosensors stent range.
“Having consistently led the industry in the development of innovative drug-eluting stents and, more recently, drug-coated stents, we are now set to reinvigorate the bare-metal stent market with the launch of Chroma”, commented Jeffrey B. Jump, President of Biosensors’ Cardiovascular Division. “This will further broaden the range of treatment options that we offer to interventional cardiologists.”
Chroma received CE Mark approval in October 2013 and is now in the process of being launched in most major European markets and selected regions in the Middle East, Africa and Asia.
Media Contact:
Wong TeckYenn
Biosensors International Group
+65 6213 5708
ty.wong@biosensors.com
About Biosensors International Group, Ltd
Biosensors International develops, manufactures and markets innovative medical devices for interventional cardiology and critical care procedures.
With the BioMatrix™ family of drug-eluting stents and the Axxess™ self-expanding bifurcation stent, we are a leader in the global coronary stent market. These stents incorporate Biolimus A9™ (BA9™), an anti-restenotic drug developed specifically for use with stents and patented by Biosensors, together with a unique abluminal biodegradable polymer coating, which fully degrades into carbon dioxide and water after six to nine months as it releases BA9. The BioMatrix family features workhorse stent platforms for a broad range of lesions, and Axxess employs a self-expanding stent platform specifically designed for treating bifurcation lesions.
The BioFreedom™ drug-coated stent, which has received CE Mark approval, underscores our technology leadership in the field of coronary stents. BioFreedom is the world’s first polymer-free stent with BA9. Chroma™, a cobalt chromium bare-metal stent featuring an innovative platform design, offers exceptional deliverability without any compromise on radial strength or recoil.
Our drug-eluting balloon range complements the stent portfolio and offers interventional cardiologists a broader range of treatment options.
For more information, please visit www.biosensors.com.
Help employers find you! Check out all the jobs and post your resume.
